Not Yet RecruitingNot Applicable

Washed Microbiota Transplantation for Allergic Rhinitis

China32 participantsStarted 2024-06-01

Plain-language summary

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18-65 years old.
✓. Meets the diagnostic criteria for allergic rhinitis.
✓. rTNSS score greater than or equal to 6 points.
✓. The subject or his/her legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.

Exclusion criteria

✕. Patients with acute nasosinusitis or upper respiratory tract infection.
✕. Patients diagnosed with chronic sinusitis, nasal septum deviation, nasal polyps, nasal tumors, and other nasal diseases or have undergone nasal surgery.
✕. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the past two weeks.
✕. Patients with poor lung function.
✕. Patients with severe liver, kidney, and heart diseases
✕. Patients with known psychiatric or neurological diseases.
✕. Patients who use antihistamines, glucocorticoids, decongestants, mast cell membrane stabilizers, leukotriene antagonists in the past two weeks.
✕. According to the judgment of the investigator, the subjects are not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subjects.

What they're measuring

Changes in the reflective total nasal symptom score (rTNSS)

Timeframe: baseline, one weeks, four weeks, twelve weeks post WMT

Trial details

NCT IDNCT06372184

SponsorThe Second Hospital of Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-06-01

Contact for this trial

Faming Zhang, MD,PhD

086-25-58509883 fzhang@njmu.edu.cn

View on ClinicalTrials.gov More Rhinitis, Allergic trials